Matinas Biopharma Holdings, Inc. (NYSE:MTNB)
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company’s proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company’s lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.
Matinas Biopharma Holdings, Inc. (NYSE:MTNB)’s Financial Overview
Matinas Biopharma Holdings, Inc. (NYSE) surged 6.78% yesterday to close its trading session at $0.93. The company has 1 year Price Target of $5. Matinas Biopharma Holdings, Inc. has 52-Week high of $1.48 and 52-Week Low of $0.324. The stock touched its 52-Week High on 1.48 and 52-Week Low on 0.32. The stock traded with the volume of 2.38 Million shares yesterday. The firm shows the market capitalization of $97.8 Million.
Matinas Biopharma Holdings, Inc. (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.03/share against the analyst consensus estimate of $-0.04/share. The difference between the actual and expected EPS is $0.01 a share with a surprise factor of 25%.
The firm is trading with SMA20 of 38.91 Percent, SMA50 of 23.47 Percent and SMA200 of 53.8 percent. Matinas Biopharma Holdings, Inc. has P/S value of 488.98 while its P/B value stands at 0. Similarly, the company has Return on Assets of -104.5 percent, Return on Equity of 0 percent and Return on Investment of 3877.1 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 1 analysts offering 12-month price forecasts for Matinas BioPharma Holdings Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +438.21% increase from the last price of 0.93.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
American International Group, Inc. (NYSE:AIG)
American International Group, Inc., world leaders in insurance and financial services, is the leading international insurance organization with operations in more than one hundred thirty countries and jurisdictions. AIG companies serve commercial, institutional and individual customers through the most extensive worldwide property-casualty and life insurance networks of any insurer. In addition, AIG companies are leading providers of retirement services, financial services and asset management around the world.
American International Group, Inc. (NYSE:AIG)’s Financial Outlook
The 16 analysts offering 12-month price forecasts for American International Group Inc have a median target of 54.00, with a high estimate of 76.00 and a low estimate of 45.00. The median estimate represents a +29.62% increase from the last price of 41.66.
American International Group, Inc. is estimated to report earnings on 02/14/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.61. The reported EPS for the same quarter last year was $0.57.
According to Zacks Investment Research, American International Group, Inc. has a Consensus Recommendation of 1.81. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 0.58% and closed its last trading session at $41.66. The company has the market capitalization of $37.3 Billion. The stock has 52-week high of $65.05 and 52-Week low of $36.16. The firm touched its 52-Week high on 65.05 and 52-Week low on 36.16. The company has volume of 4.77 Million shares. The company has a total of 895.24 Million shares outstanding.
American International Group, Inc. (NYSE) in the last quarter reported its actual EPS of $-0.34/share where the analyst estimated EPS was $0.12/share. The difference between the actual and Estimated EPS is $-0.46. This shows a surprise factor of -383.3 percent.
The company has YTD performance of 5.71 percent. Beta for American International Group, Inc. stands at 1.41 while its ATR (average true range) is 1.39. The company has Weekly Volatility of 2.63%% and Monthly Volatility of 3.48%%.
American International Group, Inc. has distance from 20-day Simple Moving Average (SMA20) of 7.13%, Distance from 50-Day Simple Moving Average of 1.74 percent and Distance from 200-Day Simple Moving Average of -17.02%.
The Company currently has ROA (Return on Assets) of -1.2 percent, Return on Equity (ROE) of -9.8 Percent and Return on Investment (ROI) of 1.9% with Gross margin of 0 percent and Operating & Profit margin of 6.3% and -12.7% respectively.